Fusion protein · Protein replacement · developed by Inozyme Pharma
INZ-701 (rhENPP1-Fc) is a recombinant fusion protein made of the extracellular domains of human ENPP1 coupled to an immunoglobulin gamma-1 Fc fragment. It is being studied in ENPP1 deficiency, autosomal recessive hypophosphatemic rickets, and generalized arterial calcification of infancy.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06046820 | Phase 3 | Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency | Terminated | BMRN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Autosomal Recessive Hypophosphatemic RicketsEctonucleotide Pyrophosphatase/Phosphodiesterase1 DeficiencyGeneralized Arterial Calcification of Infancy